Report cover image

Surgical Site Infection (SSI) Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20147060

Description

Surgical site infections are considered one of the dangerous complications of surgical procedures, accounting for nearly 20% of all hospital-acquired infections (HAIs). They have a pooled prevalence of 2.5% to 41.9% worldwide and significantly affect low and middle-income countries, especially patients in intensive care units (ICU). The increasing cases of surgical site infections are augmenting the demand for preventive and therapeutic solutions. Moreover, the rise in antibiotic-resistant bacteria is propelling the need for alternative treatments, thereby driving innovation in the drug pipeline.

Report Coverage

The Surgical Site Infection (SSI) Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into surgical site infection (SSI) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for surgical site infection (SSI). The surgical site infection (SSI) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The surgical site infection (SSI) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with surgical site infection (SSI) treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to surgical site infection (SSI).

Surgical Site Infection (SSI) Drug Pipeline Outlook

A surgical site infection (SSI) is a type of healthcare-associated infection (HAI) that occurs at the site of surgery. It exposes the patient to substantial healthcare costs as a result of severe morbidity and longer hospital stays along with the increased risk of death. Risk factors for surgical site infection include poor nutritional state, anemia, age, and obesity, among others.

Surgical site infection (SSI) therapeutics include broad-spectrum antibiotics and narrow-spectrum antibiotics targeting the specific pathogen identified through culture and sensitivity testing. Surgical site infection (SSI) emerging drugs like biologics, such as monoclonal antibodies, help in enhancing immune response and prevent infections. Further, the growing focus on non-antibiotic therapies, such as bacteriophage treatments and probiotic-based approaches, to address antibiotic resistance is anticipated to support the drug pipeline expansion in the coming years.

Surgical Site Infection (SSI) Epidemiology

A 2023 systematic review and meta-analysis found the global incidence of surgical site infections (SSIs) to be 2.5%. Subgroup analysis showed an incidence of 2.7% by WHO region and 2.5% by the survey period. The African region reported the highest incidence of surgical site infections. Further, the pooled prevalence is estimated to be 2.5% to 41.9% worldwide.

Surgical Site Infection (SSI) – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of surgical site infection (SSI) drug candidates based on several segmentations including:

By Phase
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class
  • Small Molecules
  • Monoclonal Antibodies (mAbs)
  • Peptides
  • Antimicrobial Agents
  • Other Biologics
By Route of Administration
  • Oral
  • Parenteral
  • Others
Surgical Site Infection (SSI) – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase III covers a major share of the total clinical trials, with a substantial number of surgical site infection (SSI) drugs undergoing clinical development.

Surgical Site Infection (SSI) – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the surgical site infection (SSI) pipeline analysis include small molecules, monoclonal antibodies (mAbs), peptides, antimicrobial agents, and other biologics. The surgical site infection (SSI) report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for surgical site infection (SSI).

Surgical Site Infection (SSI) Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the surgical site infection (SSI) drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed surgical site infection (SSI) therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. below is the list of a few players involved in surgical site infection (SSI) clinical trials:
  • MinaPharm Pharmaceuticals
  • MB PHARMA s.r.o.
  • PolyPid Ltd.
  • Skye Biologics Holdings, LLC
  • Ondine Biomedical Inc.
Surgical Site Infection (SSI) – Emerging Drugs Profile

Major drugs currently in the drug pipeline are as follows:

Drug: D-PLEX

Sponsored by PolyPid Ltd., the objective of this randomized clinical trial is to investigate the efficacy and safety of the surgical site infection (SSI) drug candidate D-PLEX in the prevention of post-abdominal surgery incisional infection. The study is under Phase III clinical development and has an estimated 624 participants.

Drug: ActiveMatrix

Baylor College of Medicine is conducting a Phase IV study aimed at examining the efficacy and safety of the investigational drug ActiveMatrix on spinal surgical site infection rate. The clinical trial has enrolled about 275 subjects and is expected to be completed by July 2026.

Reasons To Buy This Report

The Surgical Site Infection (SSI) Drug Report provides a strategic overview of the latest and future landscape of treatments for surgical site infection (SSI). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within surgical site infection (SSI) pipeline insights.

Key Questions Answered in the Surgical Site Infection (SSI) – Pipeline Insight Report
  • What is the current landscape of Surgical Site Infection (SSI) disease pipeline drugs?
  • Which companies/institutions are developing Surgical Site Infection (SSI) disease emerging drugs?
  • How many phase II drugs are currently present in Surgical Site Infection (SSI) disease pipeline drugs?
  • Which company is leading the Surgical Site Infection (SSI) disease pipeline development activities?
  • What is the current Surgical Site Infection (SSI) disease therapeutic assessment?
  • What are the opportunities and challenges present in the Surgical Site Infection (SSI) disease drug pipeline landscape?
  • What is the efficacy and safety profile of Surgical Site Infection (SSI) disease pipeline drugs?
  • Which companies/institutions are involved in Surgical Site Infection (SSI) disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in Surgical Site Infection (SSI) disease?
Related Reports

Post Surgical Infection Market

Infection Prevention Devices Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Surgical Site Infection (SSI)
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Types of Surgical Site Infection
3.5 Diagnosis
3.6 Treatment
4 Patient Profile: Surgical Site Infection (SSI)
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Surgical Site Infection (SSI): Epidemiology Snapshot
5.1 Surgical Site Infection (SSI) Incidence by Key Markets
5.2 Surgical Site Infection (SSI) – Patients Seeking Treatment in Key Markets
6 Surgical Site Infection (SSI): Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Surgical Site Infection (SSI): Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Surgical Site Infection (SSI), Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Surgical Site Infection (SSI) Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Surgical Site Infection (SSI) Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: D-PLEX
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Drug: ActiveMatrix
10.2.3 Drug: Ciprodiazole; Drug: Ciprofloxacin Tablets & Metronidazole tablets
10.2.4 Other Drugs
11 Surgical Site Infection (SSI) Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: Vancomycin
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Other Drugs
12 Surgical Site Infection (SSI) Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug: DUOFAG®
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Surgical Site Infection (SSI) Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Surgical Site Infection (SSI), Key Drug Pipeline Companies
14.1 MinaPharm Pharmaceuticals
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 MB PHARMA s.r.o.
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 PolyPid Ltd.
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Skye Biologics Holdings, LLC
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Ondine Biomedical Inc
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us